Life Technologies Chooses Rhenium to Distribute Products in Israel

By Life Technologies Corporation, PRNE
Wednesday, December 7, 2011

GLASGOW, Scotland, December 8, 2011 -

Life to provide broader product portfolio to Israeli customers through one distributor.

Life Technologies Corporation (Nasdaq: LIFE) today announced that it has chosen Rhenium as the principal distributor of its product portfolio for the Israeli market.  The deal represents Life’s continued growth in the region.

“We want our customers to be able to access the broad Research and Development portfolio of Life Technologies’ products and services including, amongst others, the Invitrogen and Applied Biosystems brands from one principle distributor, and have decided to consolidate our distribution channels accordingly,” said Colin McCracken, VP and Head of Sales in EMEA at Life Technologies. “Under the present arrangement this is not the case and I am confident our new plans will enhance the excellent support and reliable service our customers have come to expect.”   

Dror Israeli, Founder and Joint CEO of Rhenium said: “We are excited to be part of Life Technologies’ plans in Israel and look forward to providing customers with an excellent service in the country.”

Agentek will be authorized to continue to distribute products and fulfill customer orders on behalf of Life Technologies until December 27, 2011. The company, Medogar, which deals with the HLA product range, will continue to operate as the distributor for those products. 

Financial terms of the deal were not disclosed.

About Life Technologies

Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology company dedicated to improving the human condition.  Our systems, consumables and services enable researchers to accelerate scientific and medical advancements that make life even better.  Life Technologies customers do their work across the biological spectrum, working to advance the fields of discovery and translational research, molecular medicine, stem cell-based therapies, food safety and animal health, and 21st century forensics.  The company manufactures both molecular diagnostic and research use only products.  Life Technologies’ industry-leading brands are found in nearly every life sciences lab in the world and include innovative instrument systems under the Applied Biosystems and Ion Torrent names, as well as, the broadest range of reagents with its Invitrogen, Gibco, Ambion, Molecular Probes and Taqman products.  Life Technologies had sales of $3.6 billion in 2010, has a workforce of approximately 11,000 people, has a presence in approximately 160 countries, and possesses one of the largest intellectual property estates in the life sciences industry, with approximately 3,900 patents and exclusive licenses.  For more information on how we are making a difference, please visit our website:  Follow Life Technologies on Twitter @LIFECorporation and on Facebook.

Life Technologies’ Safe Harbor Statement

This press release includes forward-looking statements about Life Technologies’ anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies’ plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words “believe,” “plan,” “intend,” “anticipate,” “target,” “estimate,” “expect” and the like, and/or future tense or conditional constructions (”will,” “may,” “could,” “should,” etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.


Life Technologies Contact:
David Robertson, Senior Manager, Corporate Communications, EMEA


will not be displayed